4DMT To Present Interim Data From 4D-710 Phase 1/2 AEROW Clinical Trial For Cystic Fibrosis Lung Disease At European Cystic Fibrosis Society (ECFS) 46th Annual Meeting Jun. 8
Portfolio Pulse from Benzinga Newsdesk
4D Molecular Therapeutics (4DMT) will present interim data from its 4D-710 Phase 1/2 AEROW clinical trial for cystic fibrosis lung disease at the European Cystic Fibrosis Society (ECFS) 46th Annual Meeting on June 8.
May 24, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
4DMT's presentation of interim data from the 4D-710 Phase 1/2 AEROW clinical trial at the ECFS Annual Meeting may impact its stock price.
The presentation of interim data from the 4D-710 Phase 1/2 AEROW clinical trial at the ECFS Annual Meeting is an important milestone for 4DMT. However, the short-term impact on the stock price will depend on the data's reception and the market's reaction to it. As a result, the score is neutral (0) as the direction of the stock price is uncertain.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100